Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00707
|
|||||
Drug Name |
Trichloromethiazide
|
|||||
Synonyms |
(+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; Achletin; Achletin (TN); Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Ciba 7057-Su; Cretonin; Diu-Hydrin; Diu-Hydrin (TN); Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flurese (VAN); Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Jones Brand of Trichloromethiazide; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naqua (TN); Naquasone; Salurin (wadel); Schebitran; Schering Brand of Trichlormethiazide; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazide (JP15/USP/INN); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum; Trichlormethiazidum [INN-Latin]; Trichloromethiadiazide; Trichloromethiazide; Trichloromethiazide, 6; Triclordiuride; Triclormetiazida; Triclormetiazida[INN-Spanish]; Triclormetiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Triflumen (TN); Triflumen;American Urologicals Brand of Trichloromethiazide
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Edema associated with heart failure [ICD11:BD10.Z] | Approved | [1] | |||
Therapeutic Class |
Antihypertensive Agents
|
|||||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C8H8Cl3N3O4S2
|
|||||
Canonical SMILES |
C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
|
|||||
InChI |
InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
|
|||||
InChIKey |
LMJSLTNSBFUCMU-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 133-67-5
|
|||||
Pharmaceutical Properties | Molecular Weight | 380.7 | Topological Polar Surface Area | 135 | ||
Heavy Atom Count | 20 | Rotatable Bond Count | 2 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
0.6
|
|||||
PubChem CID | ||||||
PubChem SID |
10321929
,10506863
,108999
,11335541
,11360780
,11363414
,11365976
,11368538
,11372245
,11373972
,11376700
,11455198
,11461752
,11466853
,11467973
,11484652
,11486406
,11488764
,11491188
,11492182
,11494334
,14780142
,24899924
,26611959
,26747211
,26747212
,29224600
,46508880
,47440176
,47588924
,47662203
,47810669
,47885335
,47885336
,48110377
,48416658
,49698743
,49890376
,53789117
,56422224
,5663656
,57298708
,57322840
,597352
,7847724
,80830904
,8149566
,8153417
,855703
,9969
|
|||||
ChEBI ID |
CHEBI:9683
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [2] | |
References | ||||||
1 | Trichloromethiazide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8. |
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.